Related Experiment Video
Updated: Feb 8, 2026

Isolation of Stem Cells from Human Pancreatic Cancer Xenografts
Published on: September 26, 2010
Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells
Kang Ahn1, Young Moon O1, Young Geon Ji2
1Department of Physiology, School of Medicine, CHA University, Seongnam, Korea.
Purpose:
To investigate the effect of combined inhibition of protein kinase B (AKT) and SRC on the growth and metastatic potential of human pancreatic cancer cells.
Materials And Methods:
AKT and SRC were inhibited using 10-DEBC and PP2, respectively. The expression of their messenger RNAs were down-regulated by specific small interfering RNA (siRNA). Changes in pancreatic cancer cell growth and metastatic potential were determined using a cell viability assay and a xenotransplant model of pancreatic cancer, as well as cell migration and invasion assays. Signal proteins were analyzed by Western blot.
Results:
The inhibitors 10-DEBC and PP2 suppressed cell proliferation in a dose-dependent fashion in pancreatic cancer cell lines MIA PaCa-2 and PANC-1. The simultaneous inhibition of AKT and SRC at low concentrations resulted in a significant suppression of cell proliferation. Knockdown of AKT2 and SRC using siRNAs also significantly decreased cell proliferation. In a pancreatic cancer model, combined treatment with 10-DEBC and PP2 also significantly suppressed the growth of pancreatic cancer. Application of 10-DEBC with PP2 significantly reduced the metastatic potential of pancreatic cancer cells by inhibiting migration and invasion. The combined inhibition suppressed the phosphorylation of mTOR and ERK in pancreatic cancer cells.
Conclusion:
Combined targeting of AKT and SRC resulted in a synergistic efficacy against human pancreatic cancer growth and metastasis.
Insights
Combined inhibition of protein kinase B (AKT) and SRC effectively suppresses pancreatic cancer growth and metastasis. This dual targeting strategy shows synergistic efficacy in preclinical models, offering a promising therapeutic approach for pancreatic cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Pancreatic cancer is an aggressive malignancy with limited treatment options.
- Protein kinase B (AKT) and SRC are key signaling pathways implicated in cancer cell proliferation and metastasis.
Purpose of the Study:
- To evaluate the combined inhibitory effects of AKT and SRC on human pancreatic cancer growth and metastatic potential.
- To explore the underlying molecular mechanisms of this combined inhibition.
Main Methods:
- Utilized specific inhibitors (10-DEBC for AKT, PP2 for SRC) and small interfering RNA (siRNA) for gene knockdown.
- Assessed cell proliferation, migration, invasion, and Western blot analysis of key signaling proteins.
- Employed a human pancreatic cancer xenotransplant model to evaluate in vivo efficacy.
Main Results:
- Simultaneous inhibition of AKT and SRC significantly suppressed pancreatic cancer cell proliferation and tumor growth in vivo.
- Combined treatment markedly reduced cancer cell migration and invasion, indicating decreased metastatic potential.
- The dual inhibition downregulated the phosphorylation of mTOR and ERK signaling pathways.
Conclusions:
- Combined targeting of AKT and SRC demonstrates synergistic efficacy against pancreatic cancer growth and metastasis.
- This strategy presents a promising therapeutic avenue for managing pancreatic cancer progression.
Related Concept Videos
Cancer
Cancer Cell Migration through Invadopodia
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

